drugset / Trial / NCT00870402

Aldosterone in Diabetic Nephropathy

NCT00870402

Phase 4 Unknown 160 enrolled Universidad de los Andes, Chile
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether spironolactone are effective in the reduction of albuminuria and diastolic disfunction of subjects with diabetic nephropathy.

Timeline

Start
2009-03
Primary completion
2009-12
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Spironolactone Small molecule 25 mg